Aligos Therapeutics names new Principal Accounting Officer

Aligos Therapeutics, Inc. announced that its Board of Directors appointed Nikhil Aneja as the company’s Principal Accounting Officer, effective immediately.

Accepted by SEC EDGAR 02/04/2026 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aligos Therapeutics, Inc. announced that its Board of Directors appointed Nikhil Aneja as the company’s Principal Accounting Officer, effective immediately. He replaces Lesley Ann Calhoun in that specific role, while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer.

Mr. Aneja, age 49, has been Aligos’s Vice President, Finance since February 2024. His background includes senior finance and controller positions at CareDx, Blade Therapeutics and Global Blood Therapeutics, and he is a Certified Public Accountant with a Bachelor of Commerce from the University of Delhi.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Aligos Therapeutics (ALGS) disclose in this 8-K?

Aligos Therapeutics disclosed that its Board appointed Nikhil Aneja as Principal Accounting Officer, effective immediately. He succeeds Lesley Ann Calhoun in that role, while she continues serving as Executive Vice President, Chief Operating Officer and Chief Financial Officer of the company.

Who is Nikhil Aneja, the new Principal Accounting Officer of Aligos Therapeutics (ALGS)?

Nikhil Aneja is a finance executive who has served as Aligos’s Vice President, Finance since February 2024. He previously held senior finance and controller roles at CareDx, Blade Therapeutics and Global Blood Therapeutics, and is a Certified Public Accountant with a commerce degree from the University of Delhi.

Does Lesley Ann Calhoun remain in a leadership role at Aligos Therapeutics (ALGS)?

Yes. Although Nikhil Aneja has been appointed Principal Accounting Officer, Lesley Ann Calhoun continues in her existing leadership roles. She remains Executive Vice President, Chief Operating Officer and Chief Financial Officer, providing continuity in Aligos Therapeutics’ senior finance and operational management team.

What prior experience does Aligos Therapeutics’ new Principal Accounting Officer have?

Before joining Aligos, Nikhil Aneja served as Vice President, Corporate Controller at CareDx from December 2022 to February 2024. He also held finance and accounting leadership roles at Blade Therapeutics and Global Blood Therapeutics, bringing broad biopharmaceutical and diagnostics sector experience to Aligos’s finance function.

What are the key responsibilities implied by the Principal Accounting Officer role at Aligos (ALGS)?

The Principal Accounting Officer typically oversees a company’s accounting policies, financial reporting and internal controls. By appointing Vice President, Finance Nikhil Aneja to this role, Aligos formalizes his responsibility for its accounting leadership while its existing Chief Financial Officer continues overseeing broader financial strategy and operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001799448 0001799448 2026-01-29 2026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39617		82-4724808
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

One Corporate Dr., 2nd Floor South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(800) 466-6059

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ALGS		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 29, 2026, the Board of Directors of Aligos Therapeutics, Inc. (the “Company”) appointed Nikhil Aneja as the Company’s Principal Accounting Officer, effective immediately. In this role, Mr. Aneja succeeds Lesley Ann Calhoun, who continues to serve as the Company’s Executive Vice President, Chief Operating Officer & Chief Financial Officer.

Mr. Aneja, age 49, has served as the Company’s Vice President, Finance since February 2024. From December 2022 to February 2024, Mr. Aneja served as Vice President, Corporate Controller at CareDx, Inc., a diagnostic company. Prior to that, Mr. Aneja served as Vice President, Finance and Accounting at Blade Therapeutics, Inc., a biopharmaceutical company, from May 2021 to October 2022, and as Executive Director, Global Corporate Controller at Global Blood Therapeutics, Inc., a biopharmaceutical company, from September 2016 to May 2021. He received his Bachelor of Commerce from the University of Delhi and is a Certified Public Accountant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				ALIGOS THERAPEUTICS, INC.
Date: February 4, 2026				By:		/s/ Lesley Ann Calhoun
						Lesley Ann Calhoun
						Executive Vice President, Chief Operating Officer & Chief Financial Officer